Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I feasibility study of pretargeted TF2 and lutetium-177 IMP-288 in advanced colorectal cancer
NL-OMON32192Phase 1Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2008
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of hMN-14 × m734 and lutetium Lu 177-DOTA-di-HSG peptide IMP-288 in colorectal cancer (CRC) (4 cohorts), sponsored by Radboud University Medical Center. Primary endpoint: Toxicity. Started Oct 2008; status: active, not recruiting.
02
Drugs
hMN-14 × m734lutetium Lu 177-DOTA-di-HSG peptide IMP-288
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON32192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32192.